Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Yescarta Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - TennesseePolicy ID_CHS_23852026_1126

    Axicabtagene Ciloleucel (Yescarta®)

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_23852026_1126 alerts

    Get alerted when Policy ID_CHS_23852026_1126 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for axicabtagene ciloleucel in adult and pediatric patients with specified B-cell lymphomas and related compendial indications. Coverage requires applicable clinical criteria, documentation, and absence of listed exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyAxicabtagene Ciloleucel (Yescarta®)
    Policy CodePolicy ID_CHS_23852026_1126
    Change TypeNo material change
    Effective DateJanuary 30, 2027
    Next Review DateN/A
    Key ActionSubmit prior authorization before treatment with the covered indication, applicable clinical documentation, and confirmation that no exclusion applies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3 monthsMaximum authorization duration
    1 doseDose per approval period
    18+ yearsMinimum age for detailed criteria
    2+ linesRequired prior therapy for specified subtypes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    13
    Indication categories identified

    Covered Indications and Exclusions

    Adult B-cell lymphomas

    Authorization of 3 months for one dose may be granted when the member is 18 years of age or older and either of the following criteria is met.

    Adult B-cell lymphoma pathways

    • Two or more prior systemic therapy lines: The member has received prior treatment with two or more lines of systemic therapy and has a qualifying B-cell lymphoma subtype.≥2 lines

      Qualifying subtypes include DLBCL arising from follicular lymphoma; histologic transformation of indolent lymphoma to DLBCL; DLBCL; primary mediastinal large B-cell lymphoma; high-grade B-cell lymphoma, including double/triple-hit lymphoma and high-grade B-cell lymphoma NOS; HIV-related B-cell lymphomas; monomorphic post-transplant lymphoproliferative disorder, B-cell type; follicular lymphoma; gastric or nongastric extranodal marginal zone lymphoma; nodal marginal zone lymphoma; or splenic marginal zone lymphoma.

    • Relapsed or refractory disease after first-line chemoimmunotherapy: The member has received prior treatment with first-line chemoimmunotherapy and has relapsed or refractory disease with a qualifying B-cell lymphoma subtype.

      Qualifying subtypes include DLBCL; primary mediastinal large B-cell lymphoma; high-grade B-cell lymphoma, including double/triple-hit lymphoma and high-grade B-cell lymphoma NOS; HIV-related B-cell lymphomas; and monomorphic post-transplant lymphoproliferative disorder, B-cell type.

    ALK-positive large B-cell lymphoma

    Authorization of 3 months for one dose may be granted for members 18 years of age or older.

    Relapsed or refractory ALK-positive large B-cell lymphoma: The member has relapsed or refractory ALK-positive large B-cell lymphoma that is CD19-positive.Age ≥18 years

    Documentation must confirm ALK positivity and CD19 tumor expression.

    Histologic Richter transformation to DLBCL

    Authorization of 3 months for one dose may be granted for members 18 years of age or older when either criterion is met.

    • Clonally unrelated or previously untreated CLL: Disease is clonally unrelated, or the member has previously untreated CLL, with partial response, refractory disease, or progression on chemoimmunotherapy.
    • Clonally related or unknown clonal status after treated CLL: Disease is clonally related or has unknown clonal status in a member with previously treated CLL and partial response, refractory disease, or progression on prior systemic therapy.

    Primary central nervous system lymphoma

    Authorization of 3 months for one dose may be granted for members 18 years of age or older.

    Relapsed or refractory primary CNS lymphoma: The member has relapsed or refractory primary central nervous system lymphoma treated with axicabtagene ciloleucel as a single agent.Age ≥18 years

    Histologic (Richter) Transformation to DLBCL

    Authorization of 3 months for one dose may be granted when all applicable criteria are met.

    Adult Richter transformation to DLBCL

    • Qualifying disease and treatment pathway

      • Clonally unrelated or untreated CLL pathway: Disease is clonally unrelated, or the member has previously untreated CLL with partial response, refractory disease, or progression on chemoimmunotherapy.
      • Clonally related or unknown status pathway: Disease is clonally related or has unknown clonal status in a member with previously treated CLL and partial response, refractory disease, or progression on prior systemic therapy.

    Primary Central Nervous System Lymphoma

    Authorization of 3 months for one dose may be granted when all criteria are met.

    Primary CNS lymphoma: The member is 18 years of age or older and has relapsed or refractory primary central nervous system lymphoma for treatment with Yescarta as a single agent.Age ≥18 years; relapsed or refractory disease; single-agent use

    Pediatric Primary Mediastinal Large B-Cell Lymphoma

    Authorization of 3 months for one dose may be granted when all criteria are met.

    Pediatric primary mediastinal large B-cell lymphoma: The member is younger than 18 years, has relapsed/refractory primary mediastinal large B-cell lymphoma, has received prior therapy with at least two prior chemoimmunotherapy regimens, and achieved partial response.Age <18 years; ≥2 prior chemoimmunotherapy regimens; partial response

    Coverage is excluded for members with previous treatment with Yescarta or another CD19-directed CAR T-cell therapy. Coverage is also excluded for ECOG performance status ≥3—the member is not ambulatory, is not capable of all self-care, and is confined to a bed or chair for more than 50% of waking hours. Additional exclusions include inadequate and unstable kidney, liver, pulmonary, or cardiac function; active hepatitis B or hepatitis C; a clinically significant active systemic infection; or an active inflammatory disorder.

    Coverage is limited to the listed FDA-approved and compendial indications for axicabtagene ciloleucel, including specified B-cell lymphomas and related lymphoma subtypes. Uses outside those listed indications are excluded.

    Any use that is not a listed FDA-approved or compendial indication is considered experimental, investigational, and not medically necessary and is not eligible for coverage under this policy.

    Initial Therapy Authorization Pathways

    Adult B-cell lymphoma

    Authorization of 3 months for one dose may be granted for members 18 years of age or older when either adult B-cell lymphoma pathway is met.

    Adult B-cell lymphoma prior-treatment pathways

    • Two or more prior systemic therapy lines: The member has received prior treatment with two or more lines of systemic therapy and has a qualifying B-cell lymphoma subtype.≥2 lines

      Qualifying subtypes include DLBCL arising from follicular lymphoma; histologic transformation of indolent lymphoma to DLBCL; DLBCL; primary mediastinal large B-cell lymphoma; high-grade B-cell lymphoma, including double/triple-hit lymphoma and high-grade B-cell lymphoma NOS; HIV-related B-cell lymphomas; monomorphic post-transplant lymphoproliferative disorder, B-cell type; follicular lymphoma; gastric or nongastric extranodal marginal zone lymphoma; nodal marginal zone lymphoma; or splenic marginal zone lymphoma.

    • Relapsed or refractory disease after first-line chemoimmunotherapy: The member has received prior treatment with first-line chemoimmunotherapy and has relapsed or refractory disease with a qualifying B-cell lymphoma subtype.

    Prior Authorization and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Coverage may be considered when the requested use is an FDA-approved indication or a listed compendial use, all applicable approval criteria are met, and the member has no exclusion to the prescribed therapy. For eligible adult B-cell lymphoma indications, authorization may be issued for 3 months for one dose.

    • Covered compendial uses include histologic transformation of indolent lymphomas to DLBCL; HIV-related B-cell lymphomas; monomorphic post-transplant lymphoproliferative disorder (B-cell type); marginal zone lymphomas; CD19-positive ALK-positive large B-cell lymphoma; histologic (Richter) transformation to DLBCL; primary central nervous system lymphoma; and pediatric primary mediastinal large B-cell lymphoma.
    • Authorization may be granted for relapsed/refractory CD19-positive ALK-positive large B-cell lymphoma in members 18 years of age or older, subject to applicable criteria.
    Prior Authorization

    Richter Transformation to DLBCL

    Prior authorization may be granted for histologic (Richter) transformation to DLBCL in members 18 years of age or older for 3 months and one dose when the applicable disease- and treatment-history criteria are met.

    Therapy and Policy Context

    Axicabtagene ciloleucel (Yescarta) is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy used for selected aggressive B-cell lymphomas. This policy addresses coverage for specified FDA-approved and compendial uses, including histologic Richter transformation to diffuse large B-cell lymphoma, primary central nervous system lymphoma, pediatric primary mediastinal large B-cell lymphoma, and other listed B-cell lymphoma indications. Coverage is subject to the applicable clinical criteria, required documentation, and the exclusions described in the policy.

    Clinical Definitions

    ECOG performance status ≥3
    AmbulationNot ambulatory
    Self-careNot capable of all self-care
    Bed or chair confinementConfined to bed or chair more than 50% of waking hours

    Authorization Duration and Dose Limits

    Axicabtagene ciloleucel (Yescarta)
    Authorization duration3 months
    Dose quantityOne dose
    Approval periodOne dose per approval period
    Axicabtagene ciloleucel (Yescarta)
    Richter transformation to DLBCLOne dose per course
    Primary central nervous system lymphomaOne dose per course
    Pediatric primary mediastinal large B-cell lymphomaOne dose per course
    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyAxicabtagene Ciloleucel (Yescarta®)
    Policy CodePolicy ID_CHS_23852026_1126
    Change TypeNo material change
    Effective DateJanuary 30, 2027
    Next Review DateN/A
    Key ActionSubmit prior authorization before treatment with the covered indication, applicable clinical documentation, and confirmation that no exclusion applies.
    SourceLink
    On This Page
    Covered Indications and ExclusionsInitial Therapy Authorization PathwaysPrior Authorization and Submission RequirementsTherapy and Policy ContextClinical DefinitionsAuthorization Duration and Dose Limits

    Qualifying subtypes include DLBCL; primary mediastinal large B-cell lymphoma; high-grade B-cell lymphoma, including double/triple-hit lymphoma and high-grade B-cell lymphoma NOS; HIV-related B-cell lymphomas; and monomorphic post-transplant lymphoproliferative disorder, B-cell type.

    ALK-positive large B-cell lymphoma

    Authorization of 3 months for one dose may be granted for members 18 years of age or older.

    ALK-positive large B-cell lymphoma: The member has relapsed or refractory ALK-positive large B-cell lymphoma that is CD19-positive.Age ≥18 years

    Documentation must confirm ALK positivity and CD19 tumor expression.

    Histologic Richter transformation

    Authorization of 3 months for one dose may be granted for members 18 years of age or older when either Richter transformation pathway is met.

    Richter transformation pathways

    • Clonally unrelated or previously untreated CLL: Disease is clonally unrelated, or the member has previously untreated CLL with partial response, refractory disease, or progression on chemoimmunotherapy.
    • Clonally related or unknown clonal status after treated CLL: Disease is clonally related or has unknown clonal status in a member with previously treated CLL and partial response, refractory disease, or progression on prior systemic therapy.

    Primary central nervous system lymphoma

    Authorization of 3 months for one dose may be granted for members 18 years of age or older.

    Primary CNS lymphoma: The member has relapsed or refractory primary central nervous system lymphoma and Yescarta is used as a single agent.Age ≥18 years; relapsed or refractory disease; single-agent use

    Initial Therapy: Richter Transformation to DLBCL

    Authorization of 3 months for one dose may be granted for treatment of histologic (Richter) transformation to DLBCL in members 18 years of age or older when either pathway is met.

    Adult Richter transformation eligibility

    • Qualifying pathway

      • Clonally unrelated or previously untreated CLL pathway: Disease is clonally unrelated, or the member has previously untreated CLL with partial response, refractory disease, or progression on chemoimmunotherapy.
      • Clonally related or unknown clonal status pathway: Disease is clonally related or clonal status is unknown; the member has previously treated CLL; and the member has partial response, refractory disease, or progression on prior systemic therapy.

    Initial Therapy: Primary CNS Lymphoma

    Authorization of 3 months for one dose may be granted.

    Primary CNS lymphoma initial treatment: The member is at least 18 years old and has relapsed or refractory primary central nervous system lymphoma; Yescarta is used as a single agent.Age ≥18 years; relapsed or refractory disease; single agent

    Initial Therapy: Pediatric Primary Mediastinal Large B-Cell Lymphoma

    Authorization of 3 months for one dose may be granted.

    Pediatric primary mediastinal large B-cell lymphoma initial treatment: The member is younger than 18 years; disease is relapsed/refractory primary mediastinal large B-cell lymphoma; the member has received at least two prior chemoimmunotherapy regimens; and the member achieved partial response.Age <18 years; ≥2 prior chemoimmunotherapy regimens; partial response
    • Disease is clonally unrelated, or the member has previously untreated CLL, with partial response, refractory disease, or progression on chemoimmunotherapy.
    • Disease is clonally related or of unknown clonal status in a member with previously treated CLL and partial response, refractory disease, or progression on prior systemic therapy.
    Prior Authorization

    Primary CNS Lymphoma

    Prior authorization may be granted for 3 months and one dose for relapsed or refractory primary central nervous system lymphoma in members 18 years of age or older when used as a single agent.

    • Documentation must establish the primary central nervous system lymphoma diagnosis and relapsed or refractory disease status.
    Prior Authorization

    Pediatric Primary Mediastinal Large B-Cell Lymphoma

    Prior authorization may be granted for 3 months and one dose for relapsed/refractory primary mediastinal large B-cell lymphoma in members younger than 18 years when the required prior treatment and response criteria are met.

    • Member is younger than 18 years of age.
    • Member has received at least two prior chemoimmunotherapy regimens.
    • Member achieved a partial response.
    Documentation Required

    Required Clinical Documentation

    Submit the clinical documentation necessary to initiate prior authorization review. Records must demonstrate prior treatment failure and include indication-specific diagnostic confirmation when required.

    • For all indications: chart notes or medical record documentation demonstrating failure of previous lines of therapy.
    • For CD19-positive ALK-positive large B-cell lymphoma: pathology or testing confirming ALK positivity.
    • For CD19-positive ALK-positive large B-cell lymphoma: testing or analysis confirming CD19 tumor expression.
    Denial Risk

    Unlisted Indication

    Requested uses outside the listed FDA-approved or compendial indications are considered experimental, investigational, and not medically necessary.

    • Confirm that the requested indication is included among the covered FDA-approved or compendial uses before submitting the authorization request.
    Denial Risk

    Clinical Exclusions

    Coverage will not be provided when any listed exclusion applies. Review the member’s clinical status and treatment history before submitting the request.

    • Previous treatment with the requested medication or another CD19-directed chimeric antigen receptor (CAR) T-cell therapy.
    • ECOG performance status greater than or equal to 3; the member is not ambulatory, is not capable of all self-care, and is confined to bed or chair more than 50% of waking hours.
    • Inadequate and unstable kidney, liver, pulmonary, or cardiac function.
    • Active hepatitis B, active hepatitis C, or a clinically significant active systemic infection.
    • Active inflammatory disorder.